Junji Furuse

Active 2002–2025

142
Papers
23,290
Citations
74
h-index
136
i10-index

Citations

Citations per year for Junji Furuse1939: 1 citations2003: 1 citations2005: 4 citations2006: 9 citations2007: 11 citations2008: 22 citations2009: 40 citations2010: 29 citations2011: 34 citations2012: 71 citations2013: 72 citations2014: 86 citations2015: 131 citations2016: 107 citations2017: 117 citations2018: 125 citations2019: 602 citations2020: 862 citations2021: 931 citations2022: 1,026 citations2023: 969 citations2024: 1,671 citations2025: 751 citations2026: 10 citations1940–2002: no citations, so these years are not shown2004: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorChina: 1,695 citing papers, 17.3% of this breakdownUnited States: 1,605 citing papers, 16.4% of this breakdownJapan: 1,139 citing papers, 11.6% of this breakdownItaly: 656 citing papers, 6.7% of this breakdownGermany: 527 citing papers, 5.4% of this breakdownUnited Kingdom: 456 citing papers, 4.7% of this breakdownSouth Korea: 385 citing papers, 3.9% of this breakdownFrance: 374 citing papers, 3.8% of this breakdownSpain: 311 citing papers, 3.2% of this breakdownTaiwan: 212 citing papers, 2.2% of this breakdownCanada: 205 citing papers, 2.1% of this breakdownNetherlands: 147 citing papers, 1.5% of this breakdown
0%17.3%Other 21.2%

Fields

  • Medicine81.4%
  • Biochemistry, Genetics and Molecular Biology14.1%
  • Immunology and Microbiology2.6%
  • Engineering0.4%
  • Neuroscience0.3%
  • Materials Science0.2%
  • Other1%

Topics

  • Hepatocellular Carcinoma Treatment and Prognosis10.9%
  • Cholangiocarcinoma and Gallbladder Cancer Studies9%
  • Cancer Immunotherapy and Biomarkers6.9%
  • Pancreatic and Hepatic Oncology Research6.9%
  • Gallbladder and Bile Duct Disorders3.3%
  • Cancer Mechanisms and Therapy2.8%
  • Other60.2%

Coauthors

All papers

Open in search
  1. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bruno Sangro - NEJM Evidence 2022 cited by 1,432

  2. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 1,097

  3. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yuxian Bai, Olga Barajas, Susan E. Bates, Stephen Begbie, Irit Ben‐Aharon, Nina Beri, Marie‐Luise Berres, Jean‐Frédéric Blanc, Ivan Borbath, Robert Bordonaro, Mohamed Bouattour, Giovanni Brandi, Adam M. Burgoyne, Kritiya Butthongkomvong, Marcos Pedro Guedes Camandaroba, Ke Cao, Marcela Carballido, Marcela Carballido, Jen‐Shi Chen, Ming‐Huang Chen, Ming-Huang Chen, Ashley Cheng, Tai‐Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joëlle Collignon, Antonio Cubillo Gracián, S. Lindsey Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith de Vos, Maria Diab, Jacob C. Easaw, Martin Eatock, Julien Edeline, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernández, Richard S. Finn, Fábio Franke, Masayuki Furukawa, Junji Furuse, Olumide B. Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Oliver Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gümüş, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoğlu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Jun‐Eul Hwang, Mevlüde İnanç, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jiménez Fonseca, Warren Joubert, Jitlada Juengsamarn and 116 more - The Lancet 2023 cited by 1,025

  4. Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 541

  5. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jean–Luc Van Laethem, Eric Van Cutsem, Scott Berry, Mark Vincent, Bettina Müller, Felipe Rey, Ángela R. Zambrano, Joaquín Guerra, Merete Krogh, Lene Bæksgaard, Mette Yilmaz, Anneli Elme, Andrus Magi, Päivi Auvinen, Tuomo Alanko, Markus Moehler, Volker Kunzmann, Thomas Seufferlein, Peter Thuss-Patience, Eray Goekkurt, Thomas Hoehler, Georg Martin Haag, Salah‐Eddin Al‐Batran, Hugo R. Castro, Karla Alejandra Lopez, Mynor Aguilar Vasquez, Mario Sandoval, Ka On Lam, Sinéad Cuffe, Cathy Kelly, Ravit Geva, Einat Shacham‐Shmueli, Ayala Hubert, Alex Beny, Baruch Brenner, Giuseppe Aprile, Alfredo Falcone, Evaristo Maiello, Rodolfo Passalacqua, Vincenzo Montesarchio, Hiroki Hara, Keisho Chìn, Tomohiro Nishina, Yoshito Komatsu, Nozumo Machida, Shuichi Hironaka, Taroh Satoh, Takao Tamura, Naotaoshi Sugimoto, Haruhiko Cho, Yashushi Omuro, Ken Kato, Masahiro Goto, Ichinosuke Hyodo, Kazuhiro Yoshida, Hideo Baba, Taito Esaki, Junji Furuse, Wan Zamaniah Wan Mohammed, Carlos Hernández Hernández, Juan Casas Garcia, Adriana Dominguez Andrade, Katriona Clarke, Geir Olav Hjortland, Nils Glenjen, Tomasz Kubiatowski, Jassem Jacek, Marek Z. Wojtukiewicz, Sergey Lazarev, Yuri Lancukhay and 58 more - The Lancet 2018 cited by 1,316

  6. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Gut 2019 cited by 723

  7. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

    Authors: , , , , , , , , , , , , , , - Journal of Hepatology 2020 cited by 421

  8. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 400

  9. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Takeharu Yamanaka, Miki Izumi, Yasutoshi Sakamoto, Hiroko Ichiki, Masayuki Hata, Riu Yamashita, Atsushi Ohtsu, Justin I. Odegaard, Takayuki Yoshino - Nature Medicine 2020 cited by 366

  10. Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Hepatology Research 2023 cited by 269

  11. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Takuji Okusaka, Yoshihiro Sakamoto, Yasushi Kojima, Ryota Higuchi, Naoki Sasahira, Keiji Sano, Toshio Nakagohri, Yu Sunakawa, Soichiro Morinaga, Yusuke Kumamoto, Kazuya Sugimori, Tatsuya Nomura, Kazuto Shibuya, Isamu Makino, Kentaro Yamazaki, Nobumasa Mizuno, Ken Kamata, Hiroshi Wada, Kunihito Gotoh, Mitsugu Sekimoto, Tetsuo Ajiki, Ikuo Nakamura, Ikuya Miki, Hiroaki Nagano, Koji Ohta, Takehiro Okabayashi, Masayuki Furukawa, Nao Fujimori - The Lancet 2023 cited by 232

  12. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Liver Cancer 2022 cited by 128

  13. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

    Authors: , , , , , , , , , , , , , , - British Journal of Cancer 2010 cited by 752

  14. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)

    Authors: , , , , , , , , , , , , - Japanese Journal of Clinical Oncology 2018 cited by 534

  15. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Naoya Kato, Kazuhiko Shioji, Kyoko Shimizu, Toshio Nakagohri, Ken Kamata, Hiroshi Ishii, Junji Furuse - Annals of Oncology 2019 cited by 334

  16. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 107

  17. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

    Authors: , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2019 cited by 332

  18. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Liver Cancer 2023 cited by 94

  19. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

    Authors: , , , , , , , , , , , , , , , , , - Future Oncology 2020 cited by 165

  20. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

    Authors: , , , , , , , , , , , , , , , , , - Journal of Hepatology 2016 cited by 385

  21. The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective

    Authors: , , , - The Oncologist 2010 cited by 977

  22. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2011 cited by 573

  23. Chemotherapy for hepatocellular carcinoma: current status and future perspectives

    Authors: , , , , , - Japanese Journal of Clinical Oncology 2017 cited by 274

  24. Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

    Authors: , , , , , , , , , , , , , , , , , , , - JAMA 2014 cited by 569